In its complaint, BMS alleges that HHS' Health Resources and Services Administration (HRSA), which has responsibility for ...
The Minnesota Department of Health recently unveiled a pivotal report on the 340B drug pricing program, which provides ...
The 340B program has received its share of criticisms, largely due to the lack of transparency into covered entities that receive the discounts from drug manufacturers.
Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...
Bristol Myers Squibb has sued the Biden administration over payment terms for hospitals in the 340B Drug Discount Program.
In its zeal to shrink the federal government, will the coming Trump administration disrupt a discount drug program that underpins the rural hospitals serving the communities that gave him their ...
The federal 340B Drug Pricing Program — a noble idea first enacted in 1992 — needs to be brought back into the shop for ...
Minnesota has becomes the first state to release a report examining the 340B drug discount program for "safety-net" hospitals ...
Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...
Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model ...
Minnesota releases a report on the 340B Drug Pricing Program, highlighting the need for transparency in healthcare economics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback